Skip to content
Search for:
About us
Overview
History
Management Board
Ethical management
Areas of Partnership
Location
Core Technology
NexP™ Fusion Technology
NexMab™ ADC Technology
Biosimilars
Technological Outcomes
Pipeline
Overview
Project
ALT-P1
Project
ALT-P7
ALT-Q5
Project
ALT-L9
ALT-L2
ESG
ESG introduction
ESG introduction
ESG Goal
ESG Guide line
Environmental
Environmental management
Safety and Health management
Introduction
Social
Charter
Counseling Center
Consultation Application
Board of directors
Audit System
Compliance Management
Ethics Charter
Board of directors
IR
News
Reports
Notices
Career
Whom Alteogen is Looking for
Job Notice
로그인
한국어
Loading...
News
alteogen
2018-04-27T13:47:37+09:00
News
Reports
Notices
News
Number
Title
Author
Date
Notice
Dear shareholders
alteogen
|
2024.03.27
|
Votes 0
|
Views 59
alteogen
2024.03.27
Notice
Alteogen announces amendment to license agreement with MSD.
alteogen
|
2024.02.24
|
Votes 0
|
Views 543
alteogen
2024.02.24
Notice
Alteogen's Tergase® (Novel Recombinant Human Hyaluronidase Injection) Shows Excellent Immunogenicity Profile
alteogen
|
2023.09.06
|
Votes 0
|
Views 1361
alteogen
2023.09.06
Notice
Hyaluronidase : A new way to be excluded from drug price negotiations under IRA
alteogen
|
2023.08.01
|
Votes 0
|
Views 1541
alteogen
2023.08.01
Notice
Alteogen Enters Into an Exclusive License Agreement to Develop and Commercialize Biosimilar Products
alteogen
|
2023.01.06
|
Votes 0
|
Views 3364
alteogen
2023.01.06
Notice
Alteogen Announces Completion of Phase 1 Clinical Trial of Aflibercept Biosimilar in Wet AMD Patients
alteogen
|
2023.01.06
|
Votes 0
|
Views 2056
alteogen
2023.01.06
Notice
Alteogen Enters Into an Exclusive License Agreement With Intas to Develop and Commercialize Two Products
alteogen
|
2023.01.06
|
Votes 0
|
Views 1841
alteogen
2023.01.06
Notice
Alteogen Enters into a Global License Agreement with a Top Ten Pharmaceutical Company for Use of Its Hybrozyme™ Technology
alteogen
|
2023.01.06
|
Votes 0
|
Views 1871
alteogen
2023.01.06
Notice
Alteogen Enters into a Non-exclusive License Agreement with a Global Pharmaceutical Company for Use of Its Hybrozyme™Technology
alteogen
|
2023.01.06
|
Votes 0
|
Views 1608
alteogen
2023.01.06
19
Alteogen and Lynkogen Enter into an Exclusive Option Agreement
alteogen
|
2018.07.04
|
Votes 0
|
Views 2235
alteogen
2018.07.04
18
18 January 2018 Bio & Medicine Alteogen to seek US approval for clinical trials of Eylea biosimilar
alteogen
|
2018.05.28
|
Votes 0
|
Views 2483
alteogen
2018.05.28
17
23 Aug. 2017 Alteogen set to start phase I trial of ADC product in Korea
alteogen
|
2018.05.28
|
Votes 0
|
Views 1579
alteogen
2018.05.28
16
26 APR 2017 Alteogen partners with Cristalia to develop long-acting growth hormone
alteogen
|
2018.05.28
|
Votes 0
|
Views 1577
alteogen
2018.05.28
15
20 APR 2017 Alteogen to enter late-stage study of Herceptin biosimilar
alteogen
|
2018.05.28
|
Votes 0
|
Views 1426
alteogen
2018.05.28
14
29 MAR 2017 Korean firm to transfer biosimilar tech to Chinese partner
alteogen
|
2018.05.28
|
Votes 0
|
Views 1449
alteogen
2018.05.28
13
29 DEC 2016 Alteogen patents
alteogen
|
2018.05.28
|
Votes 0
|
Views 1386
alteogen
2018.05.28
12
22 DEC 2016 Alteogen clears phase 1 trial of Herceptin biosimilar in Canada
alteogen
|
2018.05.28
|
Votes 0
|
Views 1503
alteogen
2018.05.28
11
7 Oct 2016 Alteogen receives patent in Japan
alteogen
|
2018.05.28
|
Votes 0
|
Views 1415
alteogen
2018.05.28
10
7 Mar 2016 Additional N-glycosylation in the N-terminal region of recombinant human alpha-1 antitrypsin enhances the circulator
alteogen
|
2018.05.28
|
Votes 0
|
Views 1276
alteogen
2018.05.28
First
«
1
2
3
»
Last
All
Title
Content
Author
Search
Go to Top